View Older Stories View More Recent Stories

Aug 16, 2021 06:00AM Exact Sciences receives regulatory approval for the Oncotype DX Breast Recurrence Score® Program in Japan
Aug 13, 2021 09:01AM Exact Sciences (EXAS) Announces Clinical Gastroenterology and Hepatology Publishes Data Showing Oncoguard Liver Liquid Biopsy Test Delivers Enhanced Performance for Early-stage Detection of Hepatocell
Aug 13, 2021 09:00AM Clinical Gastroenterology and Hepatology Publishes Data Showing Exact Sciences' Oncoguard™ Liver Liquid Biopsy Test Delivers Enhanced Performance for Early-stage Detection of Hepatocellular Carcinom
Jul 28, 2021 04:05PM Exact Sciences Announces Second Quarter 2021 Results
Jul 28, 2021 09:31AM PAVmed (PAVM) Appoints Stanley N. Lapidus as VP and Board Member
Jul 28, 2021 09:30AM Stanley Lapidus, Founder and Former Chairman & CEO of Exact Sciences, Joins PAVmed Subsidiary Lucid Diagnostics as Vice Chairman of its Board of Directors
Jul 8, 2021 06:00AM Exact Sciences schedules second quarter 2021 earnings call
May 24, 2021 06:00AM Exact Sciences to participate in June investor conferences
May 21, 2021 08:00AM Modeling Data Showed Cologuard® Was Superior to Fecal Immunochemical Test (FIT) on Cost Effectiveness and Colorectal Cancer Incidence and Mortality
May 19, 2021 05:15PM Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021
May 18, 2021 08:05PM Exact Sciences Applauds Final Task Force Recommendation That Lowers Starting Age for Colorectal Cancer Screening to 45
May 4, 2021 04:00PM Exact Sciences Announces First Quarter 2021 Results
May 3, 2021 06:00AM Exact Sciences to participate in May investor conferences
Apr 28, 2021 06:00AM Cologuard® CRC Screening Test Most Cost-Effective Test in Medically Underserved Alaska Native People
Apr 14, 2021 06:00AM Exact Sciences Completes Acquisition of Ashion Analytics, LLC, from The Translational Genomics Research Institute, an affiliate of City of Hope
Apr 8, 2021 06:00AM Exact Sciences schedules first quarter 2021 earnings call
Feb 26, 2021 07:11AM Cathie Wood's ARK Adds ~1.7M Shares of Twitter (TWTR), Sells Apple (AAPL), Alibaba (BABA)
Feb 23, 2021 06:51AM Cathie Wood's ARK Bought Buys ~$200M More Tesla (TSLA) Monday on Sell-Off
Feb 22, 2021 06:00AM Exact Sciences to participate in March investor conferences
Feb 16, 2021 04:06PM Exact Sciences (EXAS) to Acquire Ashion
Feb 16, 2021 04:05PM Exact Sciences to Acquire Ashion Analytics and Enter Research Collaboration with City of Hope's Genomics Institute, TGen
Feb 16, 2021 04:05PM Exact Sciences Announces Fourth Quarter 2020 Results
Feb 8, 2021 08:00AM Sema4 Appoints Isaac Ro, Life Sciences Executive and Wall Street Veteran, as Chief Financial Officer
Feb 1, 2021 06:00AM Exact Sciences to participate in February investor conferences
Feb 1, 2021 06:00AM Exact Sciences schedules fourth quarter 2020 earnings call
Jan 13, 2021 02:46PM Exact Sciences (EXAS) Licenses Targeted Digital Sequencing Method to Extend Leadership in Precision Oncology
Jan 13, 2021 02:45PM Exact Sciences Licenses Targeted Digital Sequencing Method to Extend Leadership in Precision Oncology
Jan 12, 2021 02:47PM Exact Sciences (EXAS) Says New Prospective Data Demonstrate Low False-Positive Rate for Screening Average-Risk People Age 45-49 for Colorectal Cancer with Cologuar
Jan 12, 2021 02:45PM New Prospective Data Demonstrate Low False-Positive Rate for Screening Average-Risk People Age 45-49 for Colorectal Cancer with Cologuard®
Jan 10, 2021 07:30PM Exact Sciences Announces Preliminary Fourth Quarter 2020 Results
Jan 5, 2021 08:25AM Exact Sciences Completes Acquisition of Thrive Earlier Detection, Creating a Leader in Blood-Based, Multi-Cancer Screening
Dec 28, 2020 06:00AM Exact Sciences to participate in J.P. Morgan Healthcare Conference
Dec 11, 2020 09:00AM New Data at SABCS 2020 Highlight the Role of the Oncotype DX Breast Recurrence Score® Test in Shaping Clinical Practice
Dec 9, 2020 09:07AM Exact Sciences (EXAS) Says RxPONDER Study Results Demonstrate Oncotype DX Test Can Now Spare Chemotherapy Use in Majority of Women with Node-positive Early-stage Breast Cancer
Dec 9, 2020 09:00AM RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer
Nov 23, 2020 06:00AM Exact Sciences to participate in December investor conference
Nov 2, 2020 06:00AM Exact Sciences to participate in November investor conferences
Oct 27, 2020 04:36PM Exact Sciences (EXAS) Commends Task Force for Draft Updated Guidelines that include Colorectal Cancer Screening Beginning at Age 45
Oct 27, 2020 04:35PM Exact Sciences Commends Task Force for Draft Updated Guidelines that include Colorectal Cancer Screening Beginning at Age 45
Oct 27, 2020 07:12AM Exact Sciences (EXAS) to Sell $869 Million of Common Stock in Registered Direct Offering
Oct 27, 2020 07:10AM Exact Sciences Announces Entry into Agreements to Sell $869 Million of Common Stock in Registered Direct Offering
Oct 27, 2020 07:01AM Exact Sciences (EXAS) to Acquire Thrive Earlier Detection for Cash and Stock up to $2.15 Billion
Oct 27, 2020 07:01AM Exact Sciences Announces Third Quarter 2020 Results
Oct 27, 2020 07:00AM Exact Sciences To Acquire Thrive Earlier Detection, Becoming A Leader In Blood-Based, Multi-Cancer Screening
Oct 12, 2020 09:00AM Exact Sciences Introduces the Oncotype MAP™ Pan-Cancer Tissue Test to Help Guide Treatment for Patients with Advanced Cancer
Oct 9, 2020 06:00AM Exact Sciences schedules third quarter 2020 earnings call
Oct 7, 2020 06:24AM Exact Sciences (EXAS), Pfizer (PFE) Extend and Amend Cologuard Promotion Agreement
Oct 7, 2020 06:11AM Exact Sciences and Pfizer Extend and Amend Cologuard® Promotion Agreement
Sep 17, 2020 06:00AM Exact Sciences to participate in Cowen Liquid Biopsy Summit
Sep 1, 2020 04:10PM Exact Sciences to participate in September investor conference
View More Recent Stories View Older Stories